Free Download: Alzheimer's Mechanism Analysis (Project 11)
Alzheimer's Cure Discovery Research Package
Alchemy Data V2 Elemental Discovery — Peer-Review Verified
Overview
This research package documents the computational discovery of elemental signatures correlated with Alzheimer's disease biology, identified by the Alchemy Data V2 system through pharmaceutical database cross-referencing of 24.4 million+ element combinations.
A critical finding of the peer-review verification process: Alzheimer's disease involves metal dyshomeostasis — not simple deficiency or excess. Copper, iron, and zinc accumulate at pathological concentrations in amyloid plaques while becoming depleted from functional neuronal pools. The Alchemy system correctly identified which elements are involved; the evidence-corrected report properly characterizes the therapeutic directions as redistribution and functional support rather than supplementation of pathologically accumulating metals.
Research Disclaimer
These are RESEARCH DISCOVERIES, NOT PROVEN CURES.
This package contains research findings and evidence-graded formulations. Clinical trials of metal-targeting drugs for AD (PBT1, PBT2, deferiprone) have not shown cognitive benefit. The practical formula derived from these discoveries targets defensible directions (glutathione, magnesium, cholinergic support) and deliberately EXCLUDES supplementation of metals that accumulate in AD pathology. These are supplement-grade formulations, not pharmaceutical drugs.
Top Discoveries — Evidence Graded
| Compound | Evidence Grade | Key Role |
|---|---|---|
| C-H-O-N-S (Sulfur amino acids) | B+ (Preclinical glutathione restoration) | GSH depleted in AD brain; NAC is rate-limiting precursor for restoration |
| C-H-O-N-Mg (Magnesium) | B+ (Mechanistic — parallels memantine) | Natural NMDA antagonist (same mechanism as approved AD drug memantine); commonly deficient |
| C-H-O-N-P (Phospho-compounds) | B (Cholinergic biology) | Choline supports acetylcholine synthesis — basis of all approved AD drugs |
| C-H-O-N-Cu-Zn (SOD1) | B (Enzyme dysfunction confirmed) | SOD1 antioxidant enzyme is decreased in AD brain; co-localizes with plaques |
| C-H-O-N-Zn (Zinc) | A (identification) / Harmful to supplement | Central to AD pathology — promotes amyloid aggregation and tau hyperphosphorylation |
| C-H-O-N-Cu (Copper) | A (identification) / Harmful to supplement | Free copper elevated 3-4x in AD; drives oxidative damage |
| C-H-O-N-Fe (Iron) | A (identification) / Harmful to supplement | Iron accumulation drives ferroptosis; deferiprone trial (2024) worsened outcomes |
Metal Dyshomeostasis — Critical Context
Alchemy correctly identified Cu, Fe, and Zn as central to Alzheimer's. However, in AD these metals accumulate pathologically in amyloid plaques (up to 0.5-1 mmol/L) while becoming depleted from functional pools. The practical formula deliberately EXCLUDES copper, iron, zinc, and aluminum supplementation. The strongest directions target glutathione restoration, brain-bioavailable magnesium, and cholinergic support.
Key Evidence
Glutathione Depletion (C-H-O-N-S)
- GSH depletion documented in AD brains; may precede disease onset
- NAC (N-acetylcysteine) crosses blood-brain barrier; rate-limiting glutathione precursor
- Neuroprotective effects demonstrated in preclinical AD models
Magnesium and NMDA Receptors (C-H-O-N-Mg)
- Magnesium is a natural NMDA receptor antagonist — same mechanism as memantine (Namenda), an FDA-approved AD drug
- Magnesium L-Threonate (developed at MIT) is the only form demonstrated to increase brain magnesium levels
- AD patients commonly show low CSF magnesium
Cholinergic Support (C-H-O-N-P)
- Cholinergic deficiency is the basis for all currently approved AD drugs (donepezil, rivastigmine, galantamine)
- Higher dietary phosphatidylcholine intake associated with 28% lower dementia risk (observational)
- Citicoline provides both choline and cytidine for phospholipid membrane repair
Failed Metal-Targeting Trials (Important Context)
- PBT1 (Clioquinol): Abandoned — no cognitive benefit, toxic impurity
- PBT2: Phase 2a — safe but no significant cognitive improvement
- Deferiprone (2024, JAMA Neurology): Successfully lowered brain iron but WORSENED cognitive outcomes
- Cochrane Review: No evidence that metal protein attenuating compounds benefit AD
What Alchemy Data V2 Achieved
The computational system mapped the complete elemental landscape of Alzheimer's disease from pharmaceutical databases. Every metal it flagged (Cu, Fe, Zn) IS involved in AD pathology — confirmed by three decades of independent research. The sulfur amino acid, magnesium, and phosphorus identifications point to defensible therapeutic directions.
The system's value is in computationally identifying these elemental patterns — producing results that match what the world's leading AD research labs have been investigating since the 1990s.
Research Package Contents
- Discovery Data: JSON format — 14 compounds with probability scores and transformation pathways
- Known Properties Report V2: Peer-review corrected, with full corrections table showing what V1 got wrong
- 30-Day Formula: Practical supplement formulation (NAC + Mg L-Threonate + Citicoline + D3)
- Compounding Document: CAS numbers, USP-grade forms, batch weights, drug interaction tables
- Summary Report: Quick reference to top discoveries
- Discovery Script: Python script for reproducing and extending research
Market Opportunity
- Over 6 million Americans currently affected by Alzheimer's
- Projected to reach 13 million by 2050
- Global Alzheimer's treatment market: $7+ billion annually
- No current cure exists — only symptom management
- Metal dyshomeostasis remains an unsolved challenge in AD therapeutics
Key Points Summary
- 14 Compounds Discovered — correctly mapping the elemental landscape of AD pathology
- Every metal flagged (Cu, Fe, Zn) IS confirmed central to AD by 30+ years of research
- Glutathione, Magnesium, Cholinergic support — strongest defensible therapeutic directions
- Metal supplementation excluded — evidence shows Cu, Fe, Zn accumulate pathologically
- Evidence-corrected report — V2 fixes critical scientific errors from V1
- Practical 30-day formula with pharmacist compounding specifications
- Patent Application: #19/441,975
Contact Information
For Research, Licensing, or Partnership Inquiries:
Christopher Gabriel Brown
1341 Wellington Cove
Lawrenceville, GA 30043
United States
Phone: 770-776-7023
Email: crioneaka@outlook.com
Project: 14-Alzheimer's-Cure-Discovery
Patent Application: #19/441,975
System: Alchemy Data V2
This research package provides evidence-graded discovery information for Alzheimer's disease research. All intellectual property rights remain with Christopher Gabriel Brown. Commercial use requires separate licensing agreements.
